National MS Society: Commercial R&D Funding Grant

The National Multiple Sclerosis Society is dedicated to curing MS and improving the lives of those affected. Through its Pathways to Cures Research Roadmap, the Society facilitates research partnerships aimed at addressing MS progression. This initiative invites applications for innovative therapeutic strategies, emphasizing collaboration between commercial and non-profit sectors. With a strong global presence, the Society leads in MS research, striving to transform scientific advances into effective treatments and ultimately prevent the disease.

NOTE: Inquiries with Fast Forward staff are strongly encouraged .
National Multiple Sclerosis Society
As the largest multiple sclerosis organization in the world and the global leader of the MS movement, the National Multiple Sclerosis Society is the best investment to reach MS cures.
This effort, called Pathways to Cures, marshals worldwide resources and research to help accelerate discoveries.
The Pathways to Cures Roadmap outlines 3 pathways:

• STOPPING MSRestore Lost FunctionEnd MS Through Prevention
• Commercial R&D Funding

The National Multiple Sclerosis Society’s mission is to cure multiple sclerosis while empowering individuals affected by MS to live their best lives. To achieve this mission, the Society has developed the Pathways to Cures Research Roadmap. This Roadmap was developed in consultation with global scientific experts and people affected by MS and outlines a vision of the most promising research that will ultimately lead to cures for MS.
This RFA invites applications to establish research partnerships with the Society’s commercial development program, Fast Forward, LLC, to accelerate and support development of therapeutic strategies specifically relevant to the Roadmap priority of addressing MS progression and progressive forms of MS. This request for applications (RFA) is open to applicants from for-profit commercial organizations and not-for-profit research institutions worldwide (see Mechanisms of Support section for additional important details).
Examples of research and development to be supported by this RFA include, but are not limited to:Proof of concept studies using sufficiently characterized compounds or biologics.
Studies to measure target engagement or target-related pharmacodynamic effects, particularly those involving endpoints with clinical utility.
Medicinal chemistry or biologic product development optimization.
PK/ADMET studies
IND-enabling studies such as GLP toxicology, compound scale-up, process method validation